Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Protein arginine methyltransferase 5: a potential cancer therapeutic target
Yuanyang Yuan, Hong Nie
Cellular Oncology (2021) Vol. 44, Iss. 1, pp. 33-44
Closed Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

STC2 activates PRMT5 to induce radioresistance through DNA damage repair and ferroptosis pathways in esophageal squamous cell carcinoma
Kan Jiang, Xin Yin, Qingyi Zhang, et al.
Redox Biology (2023) Vol. 60, pp. 102626-102626
Open Access | Times Cited: 37
Targeting Arginine Methyltransferase PRMT5 for Cancer Therapy: Updated Progress and Novel Strategies
Jiahong Zheng, Bang Li, Yingqi Wu, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 13, pp. 8407-8427
Closed Access | Times Cited: 35
SMYD4 monomethylates PRMT5 and forms a positive feedback loop to promote hepatocellular carcinoma progression
Zhenyu Zhou, Zheng Chen, Qianlei Zhou, et al.
Cancer Science (2024) Vol. 115, Iss. 5, pp. 1587-1601
Open Access | Times Cited: 6
Synthesis and biological evaluation of 1-phenyl-tetrahydro-β-carboline-based first dual PRMT5/EGFR inhibitors as potential anticancer agents
Juan Zhang, Xuliang Liu, Na Sa, et al.
European Journal of Medicinal Chemistry (2024) Vol. 269, pp. 116341-116341
Closed Access | Times Cited: 6
PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression
Yongshuai Jiang, Yuanyang Yuan, Ming Chen, et al.
Theranostics (2021) Vol. 11, Iss. 18, pp. 9162-9176
Open Access | Times Cited: 36
BHLHE22 drives the immunosuppressive bone tumor microenvironment and associated bone metastasis in prostate cancer
Chi Yin, Min Wang, Yingzhao Wang, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 3, pp. e005532-e005532
Open Access | Times Cited: 15
Epigenetic regulation of vascular smooth muscle cell phenotypic switch and neointimal formation by PRMT5
Ni Zhu, Zhi-Fu Guo, Kyosuke Kazama, et al.
Cardiovascular Research (2023) Vol. 119, Iss. 12, pp. 2244-2255
Open Access | Times Cited: 15
PADI4 facilitates stem‐like properties and cisplatin resistance through upregulating PRMT2/IDs family in oesophageal squamous cell carcinoma
Zeyu Wang, Hao Wu, Zhaoxing Li, et al.
Clinical and Translational Medicine (2025) Vol. 15, Iss. 3
Open Access
Structure-Aided Design, Synthesis, and Biological Evaluation of Potent and Selective Non-Nucleoside Inhibitors Targeting Protein Arginine Methyltransferase 5
Deqin Rong, Kaixin Zhou, Wei Fang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 11, pp. 7854-7875
Closed Access | Times Cited: 16
PRMT5 facilitates angiogenesis and EMT via HIF-1α/VEGFR/Akt signaling axis in lung cancer
Yonghua Zheng, Huaxia Ji, Wulin Yi, et al.
Aging (2023) Vol. 15, Iss. 13, pp. 6163-6178
Open Access | Times Cited: 9
Histone methylation in pancreatic cancer and its clinical implications
Xingyu Liu, Chuan-Hao Guo, Zhi-Yuan Xi, et al.
World Journal of Gastroenterology (2021) Vol. 27, Iss. 36, pp. 6004-6024
Open Access | Times Cited: 21
Unleashing the Power of Synthetic Lethality: Augmenting Treatment Efficacy through Synergistic Integration with Chemotherapy Drugs
Yajing Du, Lulu Luo, Xinru Xu, et al.
Pharmaceutics (2023) Vol. 15, Iss. 10, pp. 2433-2433
Open Access | Times Cited: 8
Glioblastoma with PRMT5 gene upregulation is a key target for tumor cell regression
Maher Kurdi, Motaz M. Fadul, Bassam M. J. Addas, et al.
ONCOLOGIE (2024) Vol. 26, Iss. 2, pp. 239-246
Open Access | Times Cited: 2
Novel Chemicals Derived from Tadalafil Exhibit PRMT5 Inhibition and Promising Activities against Breast Cancer
Ziyan Yang, Tian Xiao, Zezhi Li, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 9, pp. 4806-4806
Open Access | Times Cited: 11
PRMT5 knockdown enhances cell viability and suppresses cell apoptosis, oxidative stress, inflammation and endothelial dysfunction in ox-LDL-induced vascular endothelial cells via interacting with PDCD4
Xiaohong Fei, Xuejiang Cen, Ruochi Zhao, et al.
International Immunopharmacology (2023) Vol. 122, pp. 110529-110529
Open Access | Times Cited: 6
Discovery of tetrahydroisoquinolineindole derivatives as first dual PRMT5 inhibitors/hnRNP E1 upregulators: Design, synthesis and biological evaluation
Wenhui Chu, Na Yang, Jinhe Zhang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 258, pp. 115625-115625
Closed Access | Times Cited: 6
Endothelial PRMT5 plays a crucial role in angiogenesis after acute ischemic injury
Qing Ye, Jian Zhang, Chen Zhang, et al.
JCI Insight (2022) Vol. 7, Iss. 9
Open Access | Times Cited: 10
Endometrial stromal PRMT5 plays a crucial role in decidualization by regulating NF-κB signaling in endometriosis
Xinyu Cai, Manlin Xu, Hui Zhang, et al.
Cell Death Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 9
PRMT5/FGFR3/AKT Signaling Axis Facilitates Lung Cancer Cell Metastasis
Yonghua Zheng, Jingjing Lu, Xiao Hu, et al.
Technology in Cancer Research & Treatment (2023) Vol. 22
Open Access | Times Cited: 5
PRMT5 Deficiency Enforces the Transcriptional and Epigenetic Programs of Klrg1+CD8+ Terminal Effector T Cells and Promotes Cancer Development
Yingxia Zheng, Zheyi Chen, Bingqian Zhou, et al.
The Journal of Immunology (2021) Vol. 208, Iss. 2, pp. 501-513
Open Access | Times Cited: 12
SMYD3 drives the proliferation in gastric cancer cells via reducing EMP1 expression in an H4K20me3-dependent manner
Yi Zeng, Gang Ma, Fenglin Cai, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 6
Open Access | Times Cited: 4
Structure-based discovery of a new series of nucleoside-derived ring-opening PRMT5 inhibitors
Yu‐Ting Chen, Zekun Wang, Junjie Zhang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116171-116171
Closed Access | Times Cited: 1
The interplay mechanism between IDH mutation, MGMT-promoter methylation, and PRMT5 activity in the progression of grade 4 astrocytoma: unraveling the complex triad theory
Maher Kurdi, Alaa Alkhotani, Abdulrahman J. Sabbagh, et al.
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2024) Vol. 32, Iss. 6, pp. 1037-1045
Open Access | Times Cited: 1
MTAP as an emerging biomarker in thoracic malignancies
Magdalena M. Brune, Spasenija Savic Prince, Tatjana Vlajnic, et al.
Lung Cancer (2024) Vol. 197, pp. 107963-107963
Open Access | Times Cited: 1
CircGSK3β mediates PD-L1 transcription through miR-338-3p/PRMT5/H3K4me3 to promote breast cancer cell immune evasion and tumor progression
Lin Liang, Mengxiang Gao, Wentao Li, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top